The Future of Ketamine and Mood Disorders In 2019, the FDA and European Commission authorized using an esketamine nasal spready underneath the model title Spravato to take care of depression. Nonetheless, as of 2021, ketamine hasn't been accredited through the FDA to treat despair or other psychological wellness disorders, and thus, the medication